0001213900-26-049399
SEC filingNutriband reported $2.0M in revenue and a $8.2M net loss for FY2026, reflecting a deliberate strategic shift toward AVERSA™ Fentanyl development — a pre-commercial phase where operating losses and negative cash flow from operations are intentional consequences of prioritizing FDA alignment and clinical readiness over near-term commercial activity.
Revenue totaled $2.0M for FY2026, recognized predominantly upon shipment to customers per the Company’s stated revenue recognition policy. This level reflects the ongoing wind-down of non-core commercial services, including contract manufacturing, as resources were reallocated entirely to AVERSA™ development. Management explicitly attributes the decline in operational cash flow to development activities — not commercial underperformance — confirming that revenue generation was never the primary objective this fiscal year.
Gross profit of $566.3K yielded a 27.8% gross margin. This metric is shaped by the Company’s cost accounting framework: finished goods and work-in-process costs include material, direct labor, other direct costs, and production overheads applied at normal operating capacity. Additionally, trademarks, intellectual property, and customer base are amortized over ten years — a fixed cost component embedded in cost of goods sold. With revenue flat and development focus intensifying, gross margin reflects structural cost allocation rather than deteriorating unit economics.
Operating income was -$8.3M, and net income was -$8.2M, with diluted EPS of -$2.58. These results stem directly from the Company’s stated strategic pivot: management confirmed that ‘with the change in our focus, our capital requirements increased substantially.’ The operating loss is not indicative of inefficiency but of sustained investment in R&D infrastructure, regulatory engagement, and clinical preparation — all necessary precursors to FDA submission and potential approval.
Net cash used in operating activities was -$5.1M, and free cash flow was -$5.1M after only $5,324 in capital expenditures. This near-identical figure underscores that virtually all cash outflow stemmed from operating expenses tied to development execution — consistent with management’s statement that ‘the decrease is primarily due to cash used in the Company’s development operations.’ There was no meaningful capital investment in growth assets; instead, liquidity was preserved through financing activities, not operational performance.